Thus, the perturbation of IGF-1 signaling, as with the use of IGF-1/R inhibitors, may negatively impact the function or survival of mature SGNs, leading to the onset of otologic AEs such as hearing loss or tinnitus. The gene discussed is IGF1; the disease is hearing loss disorder.